Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opko Embarks On Transition To Profitability With Discount Buy

Executive Summary

The life sciences company picks up Transition Therapeutics in an all-stock deal that fleshes out its pipeline.

You may also be interested in...



The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.

Transition Results Not Good Enough For Lilly?

Another Pfizer deal: Opko's once-weekly growth hormone

The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC065565

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel